Avalo Therapeutics (AVTX) Invested Capital (2016 - 2025)
Historic Invested Capital for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $91.5 million.
- Avalo Therapeutics' Invested Capital rose 33436.61% to $91.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.5 million, marking a year-over-year increase of 33436.61%. This contributed to the annual value of $133.4 million for FY2024, which is 172628.7% up from last year.
- According to the latest figures from Q3 2025, Avalo Therapeutics' Invested Capital is $91.5 million, which was up 33436.61% from $104.9 million recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Invested Capital ranged from a high of $133.4 million in Q4 2024 and a low of -$112.5 million during Q1 2024
- Moreover, its 5-year median value for Invested Capital was $14.7 million (2023), whereas its average is $24.3 million.
- The largest annual percentage gain for Avalo Therapeutics' Invested Capital in the last 5 years was 172628.7% (2024), contrasted with its biggest fall of 169578.75% (2024).
- Avalo Therapeutics' Invested Capital (Quarter) stood at $23.1 million in 2021, then crashed by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then soared by 1726.29% to $133.4 million in 2024, then tumbled by 31.37% to $91.5 million in 2025.
- Its Invested Capital stands at $91.5 million for Q3 2025, versus $104.9 million for Q2 2025 and $123.0 million for Q1 2025.